Cyclosporine
Active ingredient · 2 therapeutic classes
Sold as Ikervis · Vevizye · Vekacia · Restaysis · CEQUA
- Drug class
- Calcineurin Inhibitors
- Availability
- Prescription only
- Routes
- Ophthalmic, Oral, Intravenous
- Markets covered
- 4
- Products on record
- 62
- FDA reports (12 mo)
- 10,057
Overview
Plain-language summary, compiled from the cited regulatory records
Cyclosporine is an immunosuppressant belonging to the calcineurin inhibitors drug class [1]. It is approved for treating the signs and symptoms of dry eye disease [1].
In the market, cyclosporine is available under various brand names, including VEVYE [1]. In the past 12 months, there have been 10,057 adverse event reports associated with cyclosporine [2]. The most frequently reported adverse events include eye irritation, the perception of the drug being ineffective, off-label use, eye pain, and ocular hyperemia [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 43 | May 29, 2026 |
| CA Canada | Health Canada | 14 | December 12, 2025 |
| EU European Union | EMA | 3 | January 15, 2026 |
| US United States | FDA | 2 | February 26, 2026 |
GBUnited Kingdom· MHRA
43 products
Uses
Transplantation indications Solid organ transplantation Prevention of graft rejection following solid organ transplantation. Treatment of transplant cellular rejection in patients previously receiving other immunosuppressive agents.
Bone marrow transplantation Prevention of graft rejection following allogeneic bone marrow and stem cell transplantation. Prevention or treatment of graft-versus-host disease (GVHD).
How to take
CACanada· Health Canada
14 products
Uses
Verkazia (cyclosporine) is indicated for: • Treatment of severe vernal keratoconjunctivitis in children from 4 years of age through adolescence. 1 Pediatrics Pediatrics (4 years of age through adolescence [12 to 18 years]): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of Verkazia in pediatric patients has been established; therefore, Health Canada has authorized an indication for pediatric use.
2 Geriatrics Geriatrics (> 65 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use.
How to take
EUEuropean Union· EMA
3 products
Uses
1 Therapeutic indication Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.
How to take
USUnited States· FDA
2 products
Uses
1 INDICATIONS AND USAGE VEVYE indicated for the treatment of the signs and symptoms of dry eye disease. 1% is a calcineurin inhibitor immunosuppressant indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )
How to take
Drug interactions
Known interactions involving Cyclosporine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL001010153 · revised May 29, 2026
- [2]Health Canada (DPD) · 02484137 · revised December 12, 2025
- [3]European Medicines Agency · EMEA/H/C/004411 · revised January 15, 2026
- [4]FDA DailyMed · 0a60fccf-7e1b-44… · revised February 26, 2026 [PDF]
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.